沃诺普拉桑是一种新的竞争性酸阻塞剂;又一个向前飞跃
Maha Elsabaawy1, Ahmed Shaban1, Ahmed Ezz Al-Arab2
1Depatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koum, Menoufia, Egypt.
Przeglad gastroenterologiczny
|June 28, 2024
概括
与质子抑制剂 (PPI) 相比,基于vonoprazan的治疗显示出更高的Helicobacter pylori根除率. 这种新的治疗方法被发现是安全的,并且在接受H. pylori根除的患者中耐受良好.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 由于抗生素耐药性和不足的酸性抑制,降低了Helicobacter pylori的根除率.
- 沃诺普拉桑是一种与竞争的酸阻断剂 (P-CAB),提供快速和持续的酸抑制.
- 对于P-CABs在H.pylori根除中表现优于质子抑制剂 (PPI) 的潜力.
研究的目的:
- 评估vonoprazan在一线H. pylori根除治疗中的疗效和安全性.
- 为了比较基于vonoprazan的三重疗法与基于PPI的传统三重疗法.
主要方法:
- 这是一项随机的,非盲目的研究,涉及400名H. pylori感染的患者.
- 200名患者接受了基于诺普拉赞的三重治疗,持续了14天.
- 200名患者接受了基于PPI的三重治疗,持续14天.
主要成果:
- 在vonoprazan组中,H. pylori根除率为86%,而在PPI组中为74.5%.
- 诺普拉桑实现了显著更高的根除率 (p = 0.004).
- 两组之间没有观察到不良事件的显著差异.
结论:
- 基于诺普拉桑的治疗比基于PPI的治疗更有效,用于一线的H. pylori根除.
- 诺普拉赞是一种安全且耐受良好的选择,用于治疗H. pylori.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
965
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
965
Antiepileptic Drugs: Potassium Channel Activators
168
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
168
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
371
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
371
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
421
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
421
Depolarizing Blockers: Pharmocokinetics
317
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
317


